Company Profile
Fulgent Genetics, Inc. Stock Price, News & Analysis
Company overview
Business overview
Fulgent Genetics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Fulgent Genetics is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Fulgent Genetics follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Fulgent Genetics sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
FLGT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Fulgent’s catalysts are genomic-testing demand, oncology testing, and any update that shows the business can keep expanding its recurring lab base. The market will care about workflow adoption.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
Source: Fulgent Genetics, Inc.
- 02
Fulgent Reports Third Quarter 2025 Financial Results
Source: Fulgent Genetics, Inc.
- 03
Fulgent to Participate in Upcoming Conferences
Source: Fulgent Genetics, Inc.
- 04
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Source: Fulgent Genetics, Inc.
- 05
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Source: Fulgent Genetics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.